Key points
- AdAlta's partner SHcell approved to provide BZDS1901 to advanced mesothelioma patients in China
- Treatment to be administered at Ruijin Hospital, Hainan
- Approval follows independent safety and efficacy assessment
- Provides real-world data for AdAlta's EW-001 development
Full summary
AdAlta Limited (ASX:1AD) announced that its partner Shanghai Cell Therapy Group Co Ltd (SHcell) has received approval to provide BZDS1901, a CAR-T cell therapy, to eligible advanced mesothelioma patients in China's Hainan Boao Lecheng International Medical Tourism Pilot Zone. This approval allows patients to receive treatment at Ruijin Hospital, Hainan, following an independent assessment of the therapy's safety and possible efficacy. BZDS1901, manufactured using SHcell's first-generation process, will be provided under special access arrangements. This development provides new treatment options for patients with limited alternatives and generates real-world data that supports AdAlta's EW-001 development program in China and globally.
Outlook
The approval in China provides validation and momentum for AdAlta's EW-001 development program, offering new treatment options for patients and generating valuable real-world data.